Additional Procedures to Identify Prostate Cancer

This content has been reviewed and approved by

Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia University Medical Center
 

Transrectal ultrasound (TRUS) - This  test  uses sound wave echoes to create an image of the prostate gland to visually inspect for abnormal conditions. A transrectal ultrasound image can show enlargement of the prostate gland and detect abnormal growth in or around the prostate. Ultrasound may also be used to guide a needle to obtain a biopsy of the prostate gland and/or to guide the nitrogen probes in cryosurgery. 

Computed tomography scan (also called a CT or CAT scan) - CT is a diagnostic imaging procedure that uses a combination of x-rays and computer technology to produce cross-sectional images (often called slices) of the body. A CT scan shows detailed images of any part of the body, including the bones, muscles, fat, and organs. CT scans are more detailed than standard x-rays. 

Magnetic resonance imaging (MRI) - MRI  uses  a combination of large magnets, radio frequencies, and a computer to produce detailed images of organs and structures within the body. 

Radionuclide bone scan - This scan is a nuclear imaging method that helps to detect any cancer that has spread from the prostate gland to bones. The test involves injecting a radioactive dye into a vein that displays the image of diseased bone cells throughout the entire body on a view screen. 

Biopsy (lymph node and/or prostate) - A biopsy is a procedure that removes tissue samples from the prostate (with a needle or during surgery). The samples are examined under a microscope for the presence of cancer cells or other abnormal cells. The diagnosis of cancer is confirmed only by a biopsy. Once prostate cancer is diagnosed, two determinations are made: the stage of the cancer and the grade of the cancer. 

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Prostate Cancer News
US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

FDA staff unsure about new use for Amgen's Xgeva

February 6, 2012 — WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.

UK says home-grown cancer pill too costly to use

February 2, 2012 — LONDON (Reuters) - Britain's health cost watchdog NICE sparked a major row on Thursday by snubbing a pricey new prostate cancer pill discovered at the country's top cancer research center, a decision critics said was bad for patients and research.

Select news items provided by Reuters Health